According to the Complaint, Fibrocell Science, Inc. is a cell and gene therapy company focused on improving the lives of people with rare diseases of the skin and connective tissue.

This action stems from a proposed transaction announced on September 12, 2019, pursuant to which Fibrocell will be acquired by Castle Creek Pharmaceutical Holdings, Inc.

On September 12, 2019, Fibrocell’s Board of Directors caused the Company to enter into an agreement and plan of merger with Castle Creek. Pursuant to the terms of the Merger Agreement, Fibrocell’s stockholders will receive $3.00 in cash for each share of Fibrocell common stock they own.

On October 11, 2019, Defendants filed a Proxy Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges that the Proxy Statement omits material information with respect to the Proposed Transaction, which renders the Proxy Statement false and misleading.

This case was voluntarily dismissed on January 22, 2020.